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A B S T R A C T
This position paper introduces an assessment method using staged calculation of coefﬁcients of
impairment in spastic paresis, with its rationale and proposed use. The syndrome of deforming spastic
paresis superimposes two disorders around each joint: a neural disorder comprising stretch-sensitive
paresis in agonists and antagonist muscle overactivity, and a muscle disorder (‘‘spastic myopathy’’)
combining shortening and loss of extensibility in antagonists. Antagonist muscle overactivity includes
spastic cocontraction (misdirected descending command), spastic dystonia (tonic involuntary muscle
activation, at rest) and spasticity (increased velocity-dependent reﬂexes to phasic stretch, at rest). This
understanding of various types of antagonist resistance as the key limiting factors in paretic movements
prompts a stepwise, quantiﬁed, clinical assessment of antagonist resistances, elaborating on the
previously developed Tardieu Scale. Step 1 quantiﬁes limb function (e.g. ambulation speed in lower limb,
Modiﬁed Frenchay Scale in upper limb). The following four steps evaluate various angles X of antagonist
resistance, in degrees all measured from 08, position of minimal stretch of the tested antagonist. Step
2 rates the functional muscle length, termed XV1 (V1, slowest stretch velocity possible), evaluated as the
angle of arrest upon slow and strong passive muscle stretch. XV1 is appreciated with respect to the
expected normal passive amplitude, XN, and reﬂects combined muscle contracture and residual spastic
dystonia. Step 3 determines the angle of catch upon fast stretch, termed XV3 (V3, fastest stretch velocity
possible), reﬂecting spasticity. Step 4 measures the maximal active range of motion against the
antagonist, termed XA, reﬂecting agonist capacity to overcome passive (stiffness) and active (spastic
cocontraction) antagonist resistances over a single movement. Finally, Step 5 rates the residual active
amplitude after 15 seconds of maximal amplitude rapid alternating movements, XA15. Amplitude
decrement from XA to XA15 reﬂects fatigability. Coefﬁcients of shortening (XN – XV1)/XN, spasticity (XV1 –
XV3)/XV1, weakness (XV1 – XA)/XV1 and fatigability (XA – XA15)/XA are derived. A high (e.g., >10%)
coefﬁcient of shortening prompts aggressive treatment of the muscle disorder – e.g. by stretch programs,
such as prolonged stretch postures –, while high coefﬁcients of weakness or fatigability prompt
addressing the neural motor command disorder, e.g. using training programs such as repeated
alternating movements of maximal amplitude.
 2015 Elsevier Masson SAS. All rights reserved.
Available online at
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www.sciencedirect.comSix decades ago, Tardieu deﬁned spasticity as an increase in
stretch reﬂexes that could be characterized and measured by the
speed required to elicit the reﬂexes [1]. After these initial briskness
measurements, Tardieu moved to a measurement of the angle of
the muscle reaction to fast stretch [2]. During that period,
Ashworth published an ordinal scale to rate resistance to passive
movement in patients with spastic paresis [3]. In the era of
botulinum toxin in particular, the Ashworth scale would become
considered as a tool rating spasticity and would see its use
markedly increase [4]. Fifteen years after the publication of thatE-mail address: jean-michel.gracies@hmn.aphp.fr
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1877-0657/ 2015 Elsevier Masson SAS. All rights reserved.scale, a complex consensus deﬁnition of the word spasticity was
proposed, largely following Tardieu’s inspiration but not always
understood or followed since [5].
As will be seen below, such a strict deﬁnition of spasticity has
been useful as a way to characterize patients affected with a
common syndrome; however, it failed to adequately represent the
key issues that hamper function and quality of life in paretic
patients. The author has given the full name deforming spastic
paresis to the clinical syndrome caused by lesions involving the
corticospinal pathways. This syndrome combines a neural disorder
made of agonist paresis and antagonist overactivity (see below the
deﬁnitions of each of these items) and a soft tissue disorder
combining shortening and loss of extensibility, in muscle in
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muscle disorder, which may be termed spastic myopathy [6]. In the
full name deforming spastic paresis, the adjective deforming ﬁnds
double justiﬁcation: ﬁrst, patients see their bodies deformed in this
syndrome, a cosmetic aggression that causes a signiﬁcant
component of their loss of quality life [7]; second, if no appropriate
therapeutic program is implemented, the syndrome continues to
dynamically deform bodies over time. It seems important to
remind of such a fundamental component of a syndrome in its
name.
After revisiting the deﬁnitions and characterizations of the key
phenomena in deforming spastic paresis, this position paper
revises a stepwise method to quantify their assessment, by
proposing the staged calculation of four coefﬁcients of impairment.
1. Deﬁnitions – pathophysiology – taxonomy in deforming
spastic paresis
Deforming spastic paresis is thus a syndrome combining a
neural disorder of motor command and a muscle disorder of
extensibility loss [8]. The neural disorder entails two components,
superimposed around each joint and acting synergistically to
challenge active movements: stretch-sensitive paresis in agonists
and muscle overactivity in antagonists [8,9]. The muscle disorder,
which can be termed spastic myopathy, can be clinically
subdivided into two constitutive elements, physical shortening
and visco-elastic loss of extensibility, as a part of soft tissue
contracture, challenging both active and passive movements
[6,8]. The neural and muscular disorders of deforming spastic
paresis are unevenly distributed around joints, which creates force
imbalances and thus deformities and asymmetrical impairments
of active movement, with both muscular and neural resistances
greater in attempts at moving against the more shortened muscles
[8,9]. These symptoms of deforming spastic paresis appear in the
following order after a lesion to the central pathways of motor
command execution:
 stretch-sensitive paresis is deﬁned as a quantitative reduction of
the voluntary recruitment of agonist motor units, further
diminished by antagonist stretch [8–10]. Paresis is chronologi-
cally the ﬁrst manifestation of a central lesion to the motor
pathways. In addition, paresis of central origin will act as the
trigger of a cascade of nervous system and soft tissue
adaptations, in particular muscle adaptations that will lead to
stretch-sensitivity of virtually all subsequent symptoms
[10,11]. One example is the sensitivity of agonist paresis to
antagonist stretch, which represents one of the consequences of
soft tissue adaptations [8–10];
 soft tissue contracture manifests itself as a two-fold clinical
issue: physical shortening and – at equal length – loss of
extensibility (stiffness) by increased muscle viscosity and
elasticity, particularly obvious when applying high tensions
[8,12–20]. Soft tissue contracture originates in the muscle
aggression represented by the immobilization (complete or
partial) in short position of some muscles, which begins with the
onset of paresis [12,19]. Such immobilization is often insufﬁ-
ciently compensated, or sometimes promoted, by healthcare
teams. Muscle contracture then occurs through acute modiﬁca-
tions of gene transcription in muscle ﬁbers immobilized in short
position, with deleterious quantitative and qualitative changes
[21,22]. Overall reduced rates of protein synthesis and induced
expression of genes for disuse atrophy promoters (REDD1,
REDD2, MAFbx, MuRF1) represent changes not seen when the
muscle ﬁber is immobilized in long position [23]. This phenom-
enon follows an acute time course, as most of the contracture hasactually developed by the end of the acute/subacute period,
within the days and weeks following immobilization onset
[24]. Muscle contracture, which can be termed spastic myopathy,
as a form of myopathy characterized by both increased muscle
tension and stretch-sensitive evolution, thus represents a true
muscle disorder, essentially avoidable, that comes to superim-
pose on the neurological disorder. Contracture becomes both the
ﬁrst factor of body deformity in patients with deforming spastic
paresis [25] and, through increased spindle sensitivity in the
contractured muscle [19], a factor greatly limiting passive and
active movement (see below) [26];
 spastic muscle overactivity comprises different forms of
increased involuntary recruitment of motor units, of which
the following three, most often co-existing with one another, are
of particular importance:
 spasticity is simply deﬁned as an increase in the velocity-
dependent reﬂexes to phasic stretch, detected and measured at
rest [9]. Using such strict deﬁnition, spasticity is a concept that is
useful to the clinician for being both a simple marker of this
patient population and a clinical parameter quantiﬁable at
bedside (in contrast with functionally more important forms of
muscle overactivity, see below), provided a valid and precise
measure is used [1,2,27–31]. In addition, spasticity is somewhat
correlated with other forms of spastic muscle overactivity as it
may partially reﬂect both motoneuronal hyperexcitability and
spindle responsiveness [9,19,32–37]. However, spasticity per se
is not the main factor limiting active movement in patients with
deforming spastic paresis, with the likely exception of attempts
at fast or ballistic movements [9],
 spastic dystonia is an excessive, chronic, tonic muscle
activation of supraspinal origin, detected and measured at
rest, potentially reduced after maintained stretch of the
dystonic muscle [35–39]. Spastic dystonia is likely related to
increased involvement of brainstem descending pathways
(rubro-, vestibulo-, tecto-, and ipsilateral reticulo-spinal
pathways) undergoing abnormal branching onto deafferented
hyperexcitable motor neurons following higher lesions [40–
44]. Most of these pathways are excitatory and have reduced
capacities of neuronal rest, compared to the corticospinal
pathway [45–47]. Within the most shortened muscles, spastic
dystonia comes to superimpose on soft tissue contracture to
represent a second major factor of deformity in patients with
spastic paresis [35–39],
 spastic cocontraction is an excessive degree of antagonistic
activation elicited by voluntary agonist command [8,9,11,48–
51]. This type of overactivity is thus revealed and measured
only during voluntary command directed to the agonist; it has
supraspinal origin and is aggravated by stretch of the
cocontracting muscle [9,11,50]. Antagonist coactivation actu-
ally was the ﬁrst identiﬁed form of muscle overactivity in
patients with deforming spastic paresis, before the term
spasticity was coined [48]. Spastic cocontraction is a critical
factor of limitation – sometimes reversal – of active movement
in subjects with deforming spastic paresis [9–11,48–51].
Stretch-sensitive paresis, soft tissue contracture and spastic
muscle overactivity make up the syndrome of deforming spastic
paresis and represent the three main factors hindering movement
in this syndrome. Reciprocal potentiation ends up developing
between the muscle disorder, soft tissue contracture in the shorter
of the two muscles around a joint, and the neural disorder,
antagonist muscle overactivity in that muscle and stretch-
sensitive paresis in the opposing muscle [8,9,17,52].
A behavioral modiﬁcation typically comes to further aggravate
this picture, as a self-imposed behavior of general hypo-activity,
reduced social participation and therefore sensorimotor restriction
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body deformities and motor limitations [53–55]. Self-imposed
sensorimotor restriction becomes particularly marked for the
paretic limbs, as patients speciﬁcally disuse them in a behavior
that was initially called functional motor amnesia by Meige [56,57]
and later, perhaps more accurately, learned non-use by Taub and
Berman [58,59]. Learned non-use of the paretic limbs – sometimes
encouraged by rehabilitation systems, in particular when the care
to compensate overshadows the effort to restore – is both a
consequence of the paresis and a factor of its aggravation. This
represents the second vicious cycle that comes to imprison
patients with deforming spastic paresis [9]. Indeed, prolonged
disuse universally deteriorates central nervous system respon-
siveness, motor command capabilities and muscle mass regulation
[60–62]. In the case of a paretic limb, disuse speciﬁcally reduces
cortical excitability and plasticity in the very areas that could be
utilized to restore motor command to that limb [8,62–65].
2. From a stepwise, quantiﬁed, clinical assessment to staged
coefﬁcients of impairment
When considering the main factors of movement limitation
that are reviewed above, one comes to recognize that:
 most of the movement-limiting factors are antagonist resis-
tances (soft tissue contracture, spastic dystonia, spastic cocon-
traction, spasticity);
 at least three of the more important factors, paresis, spastic
dystonia, spastic cocontraction, are not clinically ratable, taken
individually.
Under these circumstances, a stepwise strategy of clinical
evaluation is proposed here, that leads to the deﬁnition of four
coefﬁcients of impairment around each joint. This strategy
provides both quantitative measurements and a rationale to guide
multifocal treatment. According to this strategy, clinical evaluation
of deforming spastic paresis may be ﬁrst quantiﬁed using ﬁve
steps, among which Steps 1 to 3 are already validated [30,66–
75]. This stepwise quantitative assessment and the derived
coefﬁcients may then be recorded on a log sheet, of which
examples are proposed in Appendix 1 (upper limb) and Appendix 2
(lower limb).
2.1. Step 1
Assessment begins with an objective evaluation of active (or
passive in most severe cases) functional performance at the clinic.
This initial step will actually guide both the subsequent analytical
evaluations (steps 2 to 5) and the therapeutic choices of
neurorehabilitative techniques, including potentially transient
focal muscle weakening.
In the lower limb, active function, if ambulation is possible, may
be measured by ambulation speed over 10 meters or maximal
walking speed over 2 minutes, which have excellent ecological
validity in particular [66–75]. Among the various possible testing
modalities (barefoot or with shoes, with or without assistive
device, at comfortable or fast speed, including or not sit-to-stand,
u-turn and stand-to-sit), one that may both serve as a better
indicator for real life functional mobility and carry higher
sensitivity to change should involve imposing maximal strain on
the neural motor system [76]. This can be achieved by providing
minimal assistance to the patient, for example testing gait barefoot
without assistive device if possible, at maximal rather than
comfortable speed, and including sit-to-stand, u-turns and stand-
to-sit (modiﬁed up-and-go test) [77]. For example, a 10-meter
ambulation test at maximal speed, barefoot, starting and endingseated, has been the most sensitive to change (more sensitive than
comfortable speed barefoot tests or tests with shoes) after
therapeutic interventions involving neurorehabilitation programs
(guided self-rehabilitation contracts) and repeat injections of
neuromuscular blocking agents [77,78]. In addition to quantifying
gait speed, step length and cadence, such gait tests lend themselves
to visual observation, which may also allow to qualify the gait
patterns. When observing proximal lower limb activity in spastic
paresis in particular, it is possible to deﬁne an ‘‘anterior pattern’’, in
which overactivity in quadriceps (resisting passive knee ﬂexion
during the swing phase) predominates over that in hip extensors
(hamstrings and gluteus maximus, resisting active hip ﬂexion in
swing). Anterior patterns are characterized by relatively preserved
step length but slow step speed on the paretic side (leading to a
particularly slowed gait cadence), a lack of hip extension at late
stance (due to rectus femoris shortening/overactivity), preserved
knee reextension at late swing, and a degree of knee ﬂexion that
remains below 908 in a test of rapid alternating hip ﬂexions.
Anterior patterns are commonly seen following ischemic brain
lesions in adult patients and typically point to the need to reduce
quadriceps resistances to knee ﬂexion. At the other end of the
spectrum, ‘‘posterior patterns’’ are produced when overactivity in
hip extensors (hamstrings and gluteus maximus) predominates
over that in quadriceps. Posterior patterns are characterized by
markedly reduced step length on the paretic side, preserved hip
extension at late stance, insufﬁcient knee reextension at late swing
(due to hamstrings overactivity), and a knee ﬂexion that
systematically passes 908 in a test of rapid alternating hip ﬂexions
(backward ‘‘leg recall’’). Posterior patterns are commonly seen
after spinal cord lesions (traumatic or inﬂammatory) or in infant
paresis, although in the latter patterns are often mixed and
typically point to the need to reduce mainly hip extensor
resistances to hip ﬂexion.
In the upper limb, for optimal ecological validity one may elect
to use a scale of active function directly testing everyday life tasks,
such as the Modiﬁed Frenchay Scale [79]. The scale involves video
recordings of six bimanual and four unimanual everyday tasks,
which may be stored in the patient’s ﬁle and serve later as
references [79]. After such active task evaluation, one may also
assess the patient’s subjective opinion as to the usefulness and the
daily use of the paretic upper limb (subjective evaluation
questionnaires such as the Global Subjective self-Assessment,
the Disability Assessment Scale or the Motor Activity Log) as well
as the daily use of performances in real life (actimetry, pedometry)
[79–82].
The subsequent four steps represent attempts at explaining the
functional results obtained at step 1. These tests focus on assessing
each muscle group as a potential antagonist, quantifying
resistances from it, instead of assessing agonist command as in
peripheral disorders [31]. Each of these steps measures an angle,
from zero being the theoretical position of minimal stretch of the
tested antagonist [28–31]. The ﬁrst two angle measurements (step
2 and step 3) constitute what the author has previously developed
as the ‘‘Tardieu Scale’’ [28–30]. These two angle measurements
have been shown to hold good to excellent intra- and inter-rater
reliability, both in children and adults, without the use of a
goniometer [30,75].
2.2. Step 2
The objective is to assess passive soft tissue extensibility. The
test is thus only completed after ensuring that the patient
optimally rests the tested muscles immediately prior [27–29].
One visually (without goniometer) measures the functional muscle
length (or maximal passive range of motion) for each tested muscle
group. This is done by exerting the slowest and strongest possible
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tendons, ligaments, capsules, skin, nerves, vessels) to move the
limb segment as far as possible without causing pain or
jeopardizing soft tissue integrity. The rationale behind using
extreme slowness is to minimize recruitment of stretch reﬂex
afferents, which might create a spastic reaction that would
impact on the measured amplitude [27–31]. The rationale behind
using strong stretching force (maximal force for the examiner,
compatible with preserving soft tissue integrity) is to optimally
overcome the spastic dystonia present in the assessed muscle
group, such that this type of overactivity be minimally involved in
explaining the angle of arrest. The measured angle may be termed
XV1 (V1, slowest velocity) [29–31]. In effect, XV1 (functional
muscle length) represents the amplitude that active movement
against the tested antagonist should reach in theory, if the
disorder were limited to muscle. Obviously, various non-
muscular underlying joint alterations may impact on XV1, such
as arthritis, capsulitis, or immobilization-induced joint retrac-
tions. However, these pure joint limitations should not in general
cause the major part of XV1 limitations [83]. In addition, XV1 may
not represent pure muscle or joint contractures as it might also
reﬂect extensibility losses in fascia, aponeuroses, skin, vessels,
etc. [6]. These limitations are acknowledged, hence the proposed
term functional muscle length. Depending on the degree of
invincible contracture and spastic dystonia, XV1 may be more or
less remote from the expected anatomical angle at the tested
joint, a ‘‘normal’’ angle that may be called XN (using standard
anatomical values or an estimation based on the contralateral
side in hemiparetic patients). The ratio (XN – XV1)/XN may be
useful as the coefﬁcient of shortening (‘‘functional’’ shortening)
of the tested muscle.
2.3. Step 3
The objective is to assess the response of the tested muscles to
their own stretch (spasticity), which reﬂects both motoneuronal
excitability [9,32,33] and increased transmission of the stretching
forces to the spindles [19]. The maneuver is thus also performed
after ensuring that the patient optimally rests the tested muscles
immediately prior [28–30]. One may even use a few brisk
movements in the opposite direction prior to the test, to optimize
rest in the tested muscle [28–31]. The test maneuver then consists
in stretching the muscle group of interest as fast as possible until a
catch is felt. If the catch repeatedly and reliably occurs before
functional length (XV1) is reached and is followed by a clear
release, the visually measured (without goniometer) angle of
catch then represents the threshold for a transient resistance that
is due to an elicited stretch reﬂex. Occasionally the catch is not
followed by a clear release but still reliably occurs at an angle that
is different from – and smaller than – the muscle functional length
XV1. The absence of clear release may then be explained by
residual spastic dystonia in the tested muscle or by the encounter
of visco-elastic passive resistance from other muscles of the
tested muscle group, which have not reached their stretch reﬂex
threshold. If the catch is followed by a release and then a re-catch,
this is called a clonus. The angle of catch that is obtained using this
maneuver is called XV3 (V3, fastest possible velocity for the
examiner). Depending on the presence or absence of a catch or a
clonus, one may also determine a spasticity grade, noted as Y, an
ordinal variable [28–31]. The determination of XV1, XV3 and Y
corresponds to what the author previously developed and
validated as the Tardieu Scale [28–31]. Historically, the Tardieu
scale was named and proposed in 2000 [28,29], following Held
and Pierrot-Deseilligny early attempts at standardizing Tardieu’s
historical method of clinical examination into a scale [27]. Here,
the ratio (XV1 – XV3)/XV1 may serve as the coefﬁcient of spasticity,which quantiﬁes spasticity regardless of the functional length of
the muscle.
2.4. Step 4
The objective is to assess the capacity of agonist activation to
overcome passive and active resistance of the tested muscle group
(antagonist). One thus asks the patient to accomplish one
movement of maximal amplitude against the tested muscles.
Unlike for the measures of XV1 and XV3, for which the goniometer
does not improve reliability [30], it is recommended to use a
goniometer to measure this active angle. The amplitude reached at
the arrest of the active movement represents balance between the
forces generated by agonist activation and those related to passive
(stiffness/increased visco-elasticity) and active (spastic cocontrac-
tion) resistances opposed by the tested muscle group. The
measured angle may be called XA, maximal active amplitude
against the tested muscle, over one single movement. Its
improvement may be a primary objective of the neurorehabil-
itative techniques selected. The ratio (XV1 – XA)/XV1 is the
coefﬁcient of weakness, which measures impairment of active
command against the tested antagonist, regardless of its functional
length.
2.5. Step 5
The objective is to assess the repeatibility of overcoming
passive and active resistances of the tested muscle [31]. One asks
the patient to accomplish as many movements against the tested
muscle in a given time (15 seconds for example), keeping
amplitude as large as possible on each movement. For each tested
antagonist, the maximal active amplitude still reached at the end
of the series and the mean movement frequency are recorded. The
ﬁnal maximal amplitude may be called XA15, amplitude reached
against the tested muscle after 15 seconds of maximal active
movement repetitions. The amplitude decrement from XA reﬂects
fatigability of performance, essentially of central origin [84]. The
ratio (XA – XA15)/XA is the coefﬁcient of fatigability, which
quantiﬁes amplitude decrement over a 15-second series, regard-
less of the maximal amplitude reached over a single movement.
Its improvement, as well as that of the maximal frequency of
alternating movements, may correlate with real life functional
enhancement and should be another goal of neurorehabilitation in
spastic paresis. Validation of the latter two steps (4 and 5) requires
further studies.
Taking these assessment steps may help clarify which of the
muscle or the neural disorder predominantly affects a particular
antagonist [26]. A predominant muscle disorder would be revealed
by a particularly high coefﬁcient of shortening while a prominent
neural disorder may be detected by a high coefﬁcient of weakness
or of fatigability. Depending on the situation, treatment may then
focus more on muscle lengthening or on motor training, possibly
using advanced technologies [85,86], or both.
3. Conclusion
For the clinician, the present position paper ﬁrst stresses the
importance of assessing – and thus treating – the muscle disorder–
that is inherent to spastic paresis and that creates excessive spindle
sensitivity. This muscle disorder is a true myopathy, with
histological and physiological speciﬁcities, and may be termed
‘‘spastic myopathy’’ for didactic purposes [6]. Its further deﬁnition
and characterization will require further studies [6,8]. Finding
ways to dampen spindle sensitivity and re-lengthen muscles in
spastic paresis is a crucial therapeutic challenge.
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particular, the three deﬁnitions proposed – of spastic cocontrac-
tion, spastic dystonia, and spasticity – may seem complex at ﬁrst.
They actually make the clinician able to tease out phenomena that
are highly different from one another, even though they coexist in
the same patients. These three phenomena do not present with the
same sensitivity to current chemical treatments, spasticity being
by far the more sensitive to neuromuscular blocking agents but the
least relevant functionally.
Finally, a stepwise quantiﬁed clinical assessment is introduced,
leading to the staged calculation of four impairment coefﬁcients
(shortening, spasticity, weakness, fatigability), which should help
guide the treatment towards predominantly muscular approaches
(muscle modiﬁcations endeavors, e.g. by stretch programs), neural
approaches (e.g. training programs), or both.
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